ABIO stock forecast
Our latest prediction for ARCA biopharma, Inc.'s stock price was made on the Feb. 27, 2018 when the stock price was at 0.64$.
In the short term (2weeks), ABIO's stock price should outperform the market by 0.95%. During that period the price should oscillate between -12.77% and +39.00%.
In the medium term (3months), ABIO's stock price should outperform the market by 8.56%. During that period the price should oscillate between -25.40% and +99.28%.Get email alerts
Create a solid portfolio with ABIO
About ARCA biopharma, Inc.
ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.81$ per share.
The book value per share is 0.65$
Three months stock forecastFeb. 27, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|